Related Experiment Video
Updated: Jun 19, 2026
11:06
Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
Published on: November 11, 2022
[Biodegradable systems containing prednisolone acetate for orbital administration].
Ricardo Martins Duarte Byrro1, Denise Miyashita, Verônica Batista de Albuquerque
1Faculdade de Farmácia da Universidade Federal de Minas Gerais-UFMG, Belo Horizonte (MG), Brazil.
Arquivos Brasileiros De Oftalmologia
|October 13, 2009
Summary
This study developed an injectable, extended-release prednisolone acetate (PA) microsphere formulation using poly-e-caprolactone (PCL) for orbital inflammation treatment. The PCL microspheres demonstrated satisfactory drug loading, prolonged release, and local biocompatibility in vivo.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Ophthalmology
Context:
- Orbital inflammatory diseases require effective and sustained therapeutic interventions.
- Current treatments may involve frequent administration or systemic side effects.
- Development of localized, long-acting drug delivery systems is crucial for improving patient outcomes.
Purpose:
- To evaluate an injectable, extended-release formulation of prednisolone acetate (PA) for orbital administration.
- To develop and characterize poly-e-caprolactone (PCL) microspheres encapsulating PA.
- To assess the in vitro and in vivo performance, including release kinetics and local biocompatibility.
Summary:
- Poly-e-caprolactone (PCL) microspheres containing prednisolone acetate (PA) were successfully prepared using solvent evaporation.
- Characterization confirmed feasibility, satisfactory encapsulation efficiency (43+/-7%), and stability without drug-polymer interaction.
- In vitro and in vivo studies in rabbits demonstrated prolonged PA release and absence of local toxicity, validating the system's potential.
Impact:
- The developed PCL microsphere system offers a promising alternative for sustained treatment of orbital inflammatory diseases.
- This formulation could potentially reduce treatment frequency and improve therapeutic efficacy.
- Further research may lead to advanced localized drug delivery solutions in ophthalmology.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...